Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future

Atieno, Omondi Michelle; Opanga, Sylvia; Martin, Antony; Kurdi, Amanj; Godman, Brian

doi:10.1080/13696998.2018.1484372

Cited by 48 publications

(61 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing prices for new cancer medicines, combined with increasing prevalence rates, is putting considerable strain on patients to access cancer treatments and healthcare systems to fund them (19)(20)(21)(22)(23). High reimbursed prices for new cancer medicines certainly in Europe have been enhanced by the emotive nature of cancer, capturing public, physician, and political attention (13,(24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Godman¹,

Hill²,

Simoens³

et al. 2019

GaBI J

Self Cite

View full text Add to dashboard Cite

Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to-93.1%), generic imatinib (up to-97.8%) and generic temozolomide (up to-80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some nonpatented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer

show abstract

Section: Introductionmentioning

confidence: 99%

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Godman¹,

Hill²,

Simoens³

et al. 2019

GaBI J

Self Cite

View full text Add to dashboard Cite

show abstract

“…Likewise, The mean of radiotherapy cost for those who had received radiotherapy in the private hospital and the public hospital was estimated to be $678.95 (%5.67 of the total costs) and $189.00 (%0.82 of the total costs) per patient, respectively. In the study of Omondi Michelle et al, in 2016, patients on chemotherapy alone cost an average of $1364.3; while those treated with surgery cost an average of $1265.6, and those on radiotherapy $1175.1 (30). A study by Elias et al showed that the average annual cost of cancer drugs was 6.475$ per patient, which the highest amount of drug costs were related to breast cancer (31).…”

Section: Resultsmentioning

confidence: 99%

The Cost of Breast Cancer: A Comparison Between Private and Public Hospitals

Afkar

Jalilian

Pourreza

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgrounds: Breast cancer is the most prevalent cancer among women. Breast cancer imposes a considerable economic burden on the health system. This study aimed to compare the cost of breast cancer among patients who referred to private and public hospitals in Iran (2017). Methods: This was a prevalence-based cost of illness study. A total of 179 patients were selected from private and public hospitals using the census method. The researcher-constructed checklist was used for data collection. Data were analyzed using SPSS software version 22. Results: The estimated total mean ±SD direct cost of patients who referred to the private hospital and the public hospital was $10051.78±19484.61 and $3956.33±6783.02, respectively. Further, the total mean indirect cost of patients who referred to the private hospital was lower than those referring to the public hospital at $1870.89 (%15.69 of total costs) and $22348.5 (%84.95 of total costs), respectively. These differences were statistically significant (P<0.05). Conclusions: Breast cancer imposes a substantial cost on patients, health insurance organizations and the whole society in Iran. Therefore, the adoption of effective measures for the prevention and early diagnosis of breast cancer is urgently needed.

show abstract

“…Likewise, The mean of radiotherapy cost for those who had received radiotherapy in the private hospital and the public hospital was estimated to be $678.95 (%5.67 of the total costs) and $189.00 (%0.82 of the total costs) per patient, respectively. In the study of Omondi Michelle et al, in 2016, patients on chemotherapy alone cost an average of $1364.3; while those treated with surgery cost an average of $1265.6, and those on radiotherapy $1175.1 (32). A study by Elias et al showed that the average annual cost of cancer drugs was 6.475$ per patient, which the highest amount of drug costs were related to breast cancer (33).…”

Section: Resultsmentioning

confidence: 99%

The cost of breast cancer: A comparison between private and public hospitals

Afkar

Jalilian

Pourreza

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgrounds Breast cancer is the most prevalent cancer among women. Breast cancer imposes a considerable economic burden on the health system. This study aimed to compare the cost of breast cancer among patients who referred to private and public hospitals in Iran (2017).Methods This was a prevalence-based cost of illness study. A total of 179 patients were selected from private and public hospitals using the census method. The researcher-constructed checklist was used for data collection. Data were analyzed using SPSS software version 22.Results The estimated total mean ± SD direct cost of patients who referred to the private hospital and the public hospital was $10051.78 ± 19484.61 and $3956.33 ± 6783.02, respectively. Further, the total mean indirect cost of patients who referred to the private hospital was lower than those referring to the public hospital at $1870.89 (%15.69 of total costs) and $22348.5 (%84.95 of total costs), respectively. These differences were statistically significant (P < 0.05).Conclusion Breast cancer imposes a substantial cost on patients, health insurance organizations and the whole society in Iran. Therefore, the adoption of effective measures for the prevention and early diagnosis of breast cancer is urgently needed.

show abstract

Pilot study assessing the direct medical cost of treating patients with cancer in Kenya; findings and implications for the future

Cited by 48 publications

References 30 publications

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

The Cost of Breast Cancer: A Comparison Between Private and Public Hospitals

The cost of breast cancer: A comparison between private and public hospitals

Contact Info

Product

Resources

About